A Phase III Randomized, Placebo Controlled, Double Blind Trial of Sorafenib plus Erlotinib vs. Sorafenib plus Placebo as First Line Systemic Treamtent for Hepatocellular Carcinoma (HCC)
|Effective start/end date||10/13/09 → 10/31/15|
- BAYER HEALTHCARE PHARMACEUTICALS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.